Tabas I, Myers J N, Innerarity T L, Xu X X, Arnold K, Boyles J, Maxfield F R
Department of Medicine, Columbia University, New York 10032.
J Cell Biol. 1991 Dec;115(6):1547-60. doi: 10.1083/jcb.115.6.1547.
Low density lipoprotein (LDL) and beta-very low density lipoprotein (beta-VLDL) are internalized by the same receptor in mouse peritoneal macrophages and yet their endocytic patterns differ; beta-VLDL is targeted to both widely distributed and perinuclear vesicles, whereas LDL is targeted almost entirely to perinuclear lysosomes. This endocytic divergence may have important metabolic consequences since beta-VLDL is catabolized slower than LDL and is a more potent stimulator of acyl-CoA/cholesterol acyl transferase (ACAT) than LDL. The goal of this study was to explore the determinants of beta-VLDL responsible for its pattern of endocytic targeting. Fluorescence microscopy experiments revealed that large, intestinally derived, apoprotein (Apo) E-rich beta-VLDL was targeted mostly to widely distributed vesicles, whereas small, hepatically derived beta-VLDL was targeted more centrally (like LDL). Furthermore, the large beta-VLDL had a higher ACAT-stimulatory potential than the smaller beta-VLDL. The basis for these differences was not due to fundamental differences in the means of uptake; both large and small beta-VLDL were internalized by receptor-mediated endocytosis (i.e., not phagocytosis) involving the interaction of Apo E of the beta-VLDL with the macrophage LDL receptor. However, large beta-VLDL was much more resistant to acid-mediated release from LDL receptors than small beta-VLDL. Furthermore, partial neutralization of the multiple Apo Es on these particles by immunotitration resulted in a more perinuclear endocytic pattern, a lower ACAT-stimulatory potential, and an increased sensitivity to acid-mediated receptor release. These data are consistent with the hypothesis that the interaction of the multivalent Apo Es of large beta-VLDL with multiple macrophage LDL receptors leads to a diminished or retarded release of the beta-VLDL from its receptor in the acidic sorting endosome which, in turn, may lead to the widely distributed endocytic pattern of large beta-VLDL. These findings may represent a physiologically relevant example of a previously described laboratory phenomenon whereby receptor cross-linking by multivalent ligands leads to a change in receptor targeting.
低密度脂蛋白(LDL)和β-极低密度脂蛋白(β-VLDL)在小鼠腹腔巨噬细胞中通过相同的受体被内化,但其内吞模式不同;β-VLDL靶向广泛分布的囊泡和核周囊泡,而LDL几乎完全靶向核周溶酶体。这种内吞差异可能具有重要的代谢后果,因为β-VLDL的分解代谢比LDL慢,并且比LDL更能有效刺激酰基辅酶A/胆固醇酰基转移酶(ACAT)。本研究的目的是探索决定β-VLDL内吞靶向模式的因素。荧光显微镜实验显示,来自肠道的富含载脂蛋白(Apo)E的大颗粒β-VLDL主要靶向广泛分布的囊泡,而来自肝脏的小颗粒β-VLDL的靶向更集中(类似于LDL)。此外,大颗粒β-VLDL比小颗粒β-VLDL具有更高的ACAT刺激潜力。这些差异的基础并非摄取方式的根本差异;大颗粒和小颗粒β-VLDL均通过受体介导的内吞作用(即非吞噬作用)被内化,涉及β-VLDL的Apo E与巨噬细胞LDL受体的相互作用。然而,大颗粒β-VLDL比小颗粒β-VLDL对酸性介导的从LDL受体释放具有更强的抗性。此外,通过免疫滴定对这些颗粒上的多个Apo E进行部分中和,导致更靠近核周的内吞模式、更低的ACAT刺激潜力以及对酸性介导的受体释放的敏感性增加。这些数据与以下假设一致,即大颗粒β-VLDL的多价Apo E与多个巨噬细胞LDL受体的相互作用导致β-VLDL在酸性分选内体中从其受体的释放减少或延迟,这反过来可能导致大颗粒β-VLDL广泛分布的内吞模式。这些发现可能代表了先前描述的一种实验室现象在生理上的相关实例,即多价配体使受体交联导致受体靶向改变。